Renal Transplant Infection
Conditions
Brief summary
Renal transplant candidates who have CMV-specific, CD8+ T-cells, are CMV-seropositive and carry HLA-A1 and/ or HLA- A2 alleles have a high probability to maintain this type of immunity during the three first months after the transplant, despite induction immunosuppressive therapy (thymoglobulin).
Interventions
DRUGThymoglobulin
This study will use non-probability, convenience sampling from patients kidney transplants who receive induction immunosuppressive therapy with thymoglobulin
Sponsors
Maimónides Biomedical Research Institute of Córdoba
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Renal transplant recipients with CMV-positive serology. 2. Patients with pre-transplant, CMV-specific CD8+ T cell-mediated immunity, i.e. IFNγ levels ≥0.2 UI/mL (QF-CMV Reactive). 3. Adults over 18 years of age. 4. Patients receiving induction therapy with thymoglobulin (at least a cumulative dosage of 1mg/kg). 5. Patients receiving prophylaxis with valganciclovir (900 mg/day, adjusted to kidney function) until day 90 after transplant. 6. Patients who signed an informed consent
Exclusion criteria
1. Multivisceral transplantation, including pancreas-kidney transplantation. 2. HIV infected patients. 3. Patients who cannot comply with the monitoring protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CMV-specific, CD8+ T-cell immunity | 18 months | Percentage of patients with CMV-specific, CD8+ T-cell immunity at any of the established time points for monitorization. CMV-specific, CD8+ T-cell immunity will be defined as production of IFNγ ≥0.2 UI/mL (QF-CMV Reactive). |
Countries
Spain
Outcome results
None listed